Synthesis antitumor and radiosensitizing evaluation of some novel sulfachloropyridazine derivatives / (Record no. 166586)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 05905namaa22004451i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OSt |
| 005 - أخر تعامل مع التسجيلة | |
| control field | 20250223033232.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240325s2023 |||a|||fr|m|| 000 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloguing agency | EG-GICUC |
| Language of cataloging | eng |
| Transcribing agency | EG-GICUC |
| Modifying agency | EG-GICUC |
| Description conventions | rda |
| 041 0# - LANGUAGE CODE | |
| Language code of text/sound track or separate title | eng |
| Language code of summary or abstract | eng |
| Language code of sung or spoken text | ara |
| 049 ## - Acquisition Source | |
| Acquisition Source | Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 615.19 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) | |
| Classification number | 615.19 |
| Edition number | 21 |
| 097 ## - Degree | |
| Degree | M.Sc |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
| Local Call Number | Cai01.08.05.Ph.D.2023.Sa.S. |
| 100 0# - MAIN ENTRY--PERSONAL NAME | |
| Authority record control number or standard number | Sally Samir Mohammed Mohammed Zahran, |
| Preparation | preparation. |
| 245 10 - TITLE STATEMENT | |
| Title | Synthesis antitumor and radiosensitizing evaluation of some novel sulfachloropyridazine derivatives / |
| Statement of responsibility, etc. | presented by Sally Samir Mohammed Mohammed Zahran ; Under the Supervision of Prof. Dr. Fatma Abdel-Fattah Ragab, Prof. Dr. Mostafa Mohamed Ghorab,Prof. Dr. Marwa Galal El-Gazzar,Dr. Walaa Ramadan Mahmoud. |
| 246 15 - VARYING FORM OF TITLE | |
| Title proper/short title | تشييد بعض مشتقات السلفاكلوروبيريدازين الجديدة وتقييمها كمضادات للاورام السرطانية ومحفزات للإشعاع / |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 2023. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 173 pages : |
| Other physical details | illustrations ; |
| Dimensions | 25 cm. + |
| Accompanying material | CD. |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Source | rda content |
| 337 ## - MEDIA TYPE | |
| Media type term | Unmediated |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | volume |
| Source | rdacarrier |
| 502 ## - DISSERTATION NOTE | |
| Dissertation note | Thesis (Ph.D.)-Cairo University, 2023. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc. note | Bibliography: pages 151-173. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | The goal of this research is to synthesis new compounds with antitumor effects. The research<br/>contains a short description of the rational of the combination of chemotherapy and radiotherapy in<br/>the treatment of cancer. Novel sulfachloropyridazine derivatives have been synthesized and are<br/>expected to be active as anticancer drugs. The research includes a detailed explanation of the<br/>synthesis methods that used in the preparation of 48 new compounds. The chemical structure of<br/>these compounds has been verified by spectral analysis such as infrared, 1H-NMR, 13C-NMR,<br/>elemental analysis, and mass. And then, the synthesized compounds were subjected to in vitro<br/>cytotoxic screening against a panel of 60 cancer cell lines in one dose assay by National Cancer<br/>Institute. The most potent fourteen derivatives were tested for their antiangiogenic activity by<br/>measuring their ability to inhibit VEGFR-2. Then, the most potent compounds as VEGFR-2<br/>inhibitors were further evaluated for their ability to inhibit other enzymes responsible for<br/>angiogenesis such as PDGFR, EGFR and FGFR-1. On the other hand, the IC50 of the most potent<br/>compounds against certain human cancer cell lines were determined as well as the study the<br/>augmenting effect of γ-radiation on these compounds that showed significant effectiveness as anti-<br/>cancer drugs. In addition, the ability of the most potent two derivatives to inhibit cell migration on<br/>HUVEC cells and their effect on cell cycle on UO-31 cells has been studied. Also, an apoptotic<br/>study of these two compounds was carried out by measuring their effect on caspase-3, Bax and<br/>BCl-2 on UO-31 cells. Finally, the most fourteen compounds were docked in the active site of the<br/>VEGFR-2 kinase enzyme to give an idea if these compounds could act as VEGFR-2 kinase<br/>inhibitors |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | يهدف هذا البحث الي تشييد مركبات جديدة ذات فاعلية مضادة للاورام السرطانية و يحتوي البحث علي اسباب الجمع بين العلاج الكيميائي و الاشعاعي في علاج السرطان.<br/>تم تحضير بعض مشتقات السلفاكلوروبيريدازين الجديدة التي يتوقع لها نشاطا كمضادات للاورام السرطانية. <br/>و يحتوي البحث علي وصفا تفصيليا لطرق الكيميائية المستخدمة لتحضير 48 مركبا جديدا, و قد تم التحقق من التركيب البنائي لهذه المركبات عن طريق التحاليل الدقيقة للعناصر و الأشعة تحت الحمراء و الرنيين المغناطيسي, و لقد تم تقييم فاعلية هذه المركبات الجديدة علي خلايا الأورام السرطانية الأدمية المختلفة، و كذلك قد تم اختبار قدرة بعض المركبات علي تثبيط تولد الاوعية الدموية (Angiogensis)و ذلك عن طريق تثبيط فاعلية انزيمات VEGFR , PDGFR , EGFRو FGFR , بالاضافة الي اختبار فاعلية المركبات الاكثر تثبيطا لانزيم VEGFR-2 و الاكبر فاعلية علي خلايا الاورام السرطانية علي تحليل دورة الخلية و اختبار تاثيرها تجاه موت الخلايا المبرمج. الي جانب دراسة التأثير التحفيزى للتشعيع الجامي علي تأثير هذه المركبات علي خلايا ادمية للسرطان. بالإضافة إلي ذلك تم إرساء هذه المركبات في الموقع النشط لإنزيم VEGFR-2 لاستيضاح امكانية استخدام هذه المركبات كمضادات VEGFR-2 Kinase و بالتالي امكانية استخدمها كمضادات للاورام السرطانية<br/> |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE | |
| Issues CD | Issued also as CD |
| 546 ## - LANGUAGE NOTE | |
| Text Language | Text in English and abstract in Arabic & English. |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Pharmaceutical Chemistry |
| Source of heading or term | qmark |
| 653 #0 - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | Sulphachloropyridazine |
| -- | quinazolinone |
| -- | antitumor |
| -- | VEGFR- 2, Apoptosis |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Fatma Abdel-Fattah Ragab |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mostafa Mohamed Ghorab |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Marwa Galal El-Gazzar |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Walaa Ramadan Mahmoud |
| Relator term | thesis advisor. |
| 900 ## - Thesis Information | |
| Grant date | 01-01-2023 |
| Supervisory body | Fatma Abdel-Fattah Ragab |
| -- | Mostafa Mohamed Ghorab |
| -- | Marwa Galal El-Gazzar |
| -- | Walaa Ramadan Mahmoud |
| Universities | Cairo University |
| Faculties | Faculty of Pharmacy |
| Department | Department of Pharmaceutical Chemistry |
| 905 ## - Cataloger and Reviser Names | |
| Cataloger Name | Eman Ghareeb |
| Reviser Names | Huda |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Dewey Decimal Classification |
| Koha item type | Thesis |
| Edition | 21 |
| Suppress in OPAC | No |
| Source of classification or shelving scheme | Home library | Current library | Date acquired | Inventory number | Full call number | Barcode | Date last seen | Effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|
| Dewey Decimal Classification | المكتبة المركزبة الجديدة - جامعة القاهرة | قاعة الرسائل الجامعية - الدور الاول | 25.03.2024 | 88178 | Cai01.08.05.Ph.D.2023.Sa.S. | 01010110088178000 | 25.03.2024 | 25.03.2024 | Thesis |